Rodriguez-Morales Alfonso J, Rodriguez-Morales Andrea Gabriela, Méndez Claudio A, Hernández-Botero Sebastián
Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda Colombia.
Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, Pereira, Colombia.
Curr Trop Med Rep. 2020;7(3):75-78. doi: 10.1007/s40475-020-00205-2. Epub 2020 Apr 18.
In this review, we discuss the current implications of the changing genomic epidemiology of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), etiological agent of the Coronavirus Disease 2019 (COVID-19) and its potential relationship with the change of clinical manifestations in patients with confirmed infection.
Over the course of the current pandemic, the virus has been found more diverse in new countries. Simultaneously, also new clinical manifestations are observed, particularly more prominent gastrointestinal and neurological findings.
SARS-CoV-2/COVID-19 is changing not only its epidemiology, but also its genomic diversity and clinical manifestations, both aspects coupled, needs to be considered in the study of this ongoing pandemic.
在本综述中,我们讨论了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基因组流行病学变化的当前影响,该病毒是2019冠状病毒病(COVID-19)的病原体,及其与确诊感染患者临床表现变化的潜在关系。
在当前大流行过程中,该病毒在新的国家被发现具有更多样性。同时,也观察到了新的临床表现,特别是更突出的胃肠道和神经学表现。
SARS-CoV-2/COVID-19不仅在改变其流行病学,还在改变其基因组多样性和临床表现,在对这场持续大流行的研究中,需要综合考虑这两个方面。